Kelsie M. LaBarbera

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

G. Rishton, Z. Ni, Jason Zhang, 2021, ACS medicinal chemistry letters.

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein

G. Rishton, G. Look, N. Izzo, 2020, Journal of neuroscience research.

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

L. Schneider, K. Blennow, Claire Williams, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery

N. Izzo, Raymond Yurko, Susan M. Catalano, 2021, Journal of Neuroscience Methods.

Explorer Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer’s disease modification

L. Schneider, K. Blennow, S. DeKosky, 2021 .